Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
美适医疗与EndoGastric Solutions签署了一项价值约1.05亿美元的资产购买协议；更新FY24财务指引，每股收益从3.28-3.35美元调整为3.22-3.31美元，预估为3.33美元；营业收入从13.1-13.25亿美元调整为13.2-13.4亿美元。
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs $1.32B Est.
Merit Medical与EndoGastric Solutions签署资产购买协议，总现金对价约1.05亿美元；更新2024财年的财务指引，将每股收益从3.28-3.35美元调整至3.22-3.31美元，而市场预期为3.33美元；营业收入从13.1亿美元至13.25亿美元调整至13.2亿美元-13.4亿美元，市场预期为13.2亿美元。
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD).
Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint.
Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition.
资产收购扩大了Merit的内窥镜组合，为患有慢性胃食管反流病（GERD）的患者提供了微创解决方案。
通过现有的商业足迹，在关键的胃肠内窥镜市场上预计资产收购将每年增加约3000万美元的营业收入。
Merit在独立经营指导下重申全年2024年财务指引，并更新全年2024年财务指引以包括预计本次资产收购的部分年度影响。
SOUTH JORDAN, Utah...
202...
登录免费看全文
登录/注册